Results 11 to 20 of about 1,569,733 (298)

In silico prediction of telomerase reverse transcriptase inhibitors using modified retinol for the treatment of arsenical cancer [PDF]

open access: yesBangabandhu Sheikh Mujib Medical University Journal, 2016
Retinol molecule was modified to predict the inhibitors of telomerase reverse transcriptase for the treatment of arsenical cancer through in silico study. Telomerase activity is expressed in the cancerous conditions which can be the target for anticancer
Kipchu Tshering, Mir Misbahuddin
doaj   +2 more sources

Reverse transcriptase inhibitors diminish systemic proinflammatory responses to bacterial pathogens [PDF]

open access: yesmBio
Bacterial infections can induce exuberant immune responses that can damage host tissues. Previously, we demonstrated that systemic Escherichia coli infection in mice causes tissue damage in the liver. This liver necrosis is associated with the expression
Karthik Hullahalli   +5 more
doaj   +2 more sources

HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors [PDF]

open access: yesVirology Journal
The human T-lymphotropic virus type 1 (HTLV-1) infects millions of people globally and is endemic to various resource-limited regions. Infections persist for life and are associated with increased susceptibility to opportunistic infections and severe ...
Nicolas Tardiota   +4 more
doaj   +2 more sources

Approved HIV reverse transcriptase inhibitors in the past decade [PDF]

open access: yesActa Pharmaceutica Sinica B, 2022
HIV reverse transcriptase (RT) inhibitors are the important components of highly active antiretroviral therapies (HAARTs) for anti-HIV treatment and pre-exposure prophylaxis in clinical practice.
Guangdi Li, Yali Wang, Erik De Clercq
doaj   +2 more sources

Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors [PDF]

open access: yesCommunications Chemistry, 2023
HIV-1 reverse transcriptase is one of the most attractive targets for the treatment of AIDS. However, the rapid emergence of drug-resistant strains and unsatisfactory drug-like properties seriously limit the clinical application of HIV-1 non-nucleoside ...
Xiangyi Jiang   +17 more
doaj   +2 more sources

Proposal of pharmacophore model for HIV reverse transcriptase inhibitors: Combined mutational effect analysis, molecular dynamics, molecular docking and pharmacophore modeling study [PDF]

open access: yesInternational Journal of Immunopathology and Pharmacology
Objectives: Antiretroviral therapy (ART) efficacy is jeopardized by the emergence of drug resistance mutations in HIV, compromising treatment effectiveness.
Azzeddine Annan   +7 more
doaj   +2 more sources

The Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of HIV Infections (AIDS)

open access: yes, 2013
The majority of the drugs currently used for the treatment of HIV infections (AIDS) belong to either of the following three classes: nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).
Erik De Clercq, De Clercq, Erik
openaire   +3 more sources

Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal. [PDF]

open access: yesPLoS ONE, 2012
IntroductionCurrent Portuguese HIV treatment guidelines recommend initiating antiretroviral therapy with a regimen composed of two Nucleoside Reverse Transcriptase Inhibitors plus one Non-nucleoside Reverse Transcriptase Inhibitor (2NRTI+NNRTI) or two ...
Filipa Aragão   +2 more
doaj   +1 more source

Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites [PDF]

open access: yes, 2000
Recently, significant numbers of individuals with primary human immunodeficiency virus (HN) infection have been found to harbor viral strains with reduced susceptibility to antiretroviral drugs.
Jeannette M. Whitcomb   +27 more
core   +1 more source

Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda. [PDF]

open access: yes, 2014
We investigated phenotypic and genotypic resistance after 2 years of first-line therapy with two HIV treatment regimens in the absence of virological ...
Awio, P.   +70 more
core   +1 more source

Home - About - Disclaimer - Privacy